Loading viewer...
investor_presentation
Format: PDF investor_presentation
Calithera Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting tumor and immune cell metabolism. The company's lead program, CB-839 (glutaminase inhibitor), is entering Phase 2 trials with a clinical collaboration with Bristol Myers Squibb/Opdivo, while CB-1158 (arginase inhibitor) is in Phase 1 development in partnership with Incyte.
presentation
investor_presentation
31 Pages
Feintool Group
Flight Centre Scott Dunn Acquisition 2023
investor_presentationinvestor_presentation
61 Pages
Flight Centre Travel Group